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Sodium–glucose cotransporter 2 inhibi-
tors (SGLT2i) have recently been associ-
ated with diabetic ketoacidosis (DKA).
Initial case reports were largely among pa-
tients using SGLT2i off label in the setting
of type 1 diabetes and were unusual be-
cause of limited associated hyperglycemia
(1). More recently, the problem has been
specifically noted in patients with type 2
diabetes (2). Meta-analysis of data from
initial randomized controlled trials of
SGLT2i suggests little risk of DKA (,0.1%)
in patients with type 2 diabetes (3).
To better define the scope of the
problem in clinical practice, we con-
ducted a search of three academic health
care systems’ electronic health records.
The study was approved by institutional
review boards. Patients were selected
from all emergency and inpatient en-
counters between 1 January 2013 and
30 April 2016 that contained the diagno-
sis codes for ketosis or acidosis (ICD-9
codes: 250.10, 250.11, 250.12, 250.13,
276.2, 790.6; ICD-10 codes: E08.10,
E08.11, E09.10, E09.11, E10.10, E10.11,
E13.10, E13.11, E11.65, E11.69, E87.2)
and had an SGLT2i noted in a medication
list. Individuals who met prespecified cri-
teria for DKA with arterial pH ,7.3, ve-
nous pH ,7.27, serum bicarbonate ,18
mEq/L, positive urine or serum ketones
per institutional laboratory cutoffs, or an
anion gap .10 were included.
A total of 11,197 individuals had a pre-
scription for SGLT2i documented in a
medication list and 39 individuals met
the criteria for DKA. Details are provided
in Supplementary Table 1. Of the DKA
cases, 74% appeared to have type 2 di-
abetes. Glucose #300 mg/dL was noted
at presentation of DKA in 26 of the
39 cases (72%). The mean glucose at
presentation was 328 mg/dL, median
266 mg/dL, and range 125–904 mg/dL.
With respect to precipitating causes,
49% had nausea/vomiting, although it is
unclear if that was a cause, contributor,
or consequence of the DKA; 67% had an
obvious other precipitating event such
as surgery, insulin dose reduction, or de-
creased oral intake and weight loss.
This is the largest andmost comprehen-
sive case series of DKA associated with
the use of SGLT2i. Uncertainty about the
incidence rate of DKA among SGLT2i-
treated patients in our institutions is
substantial because we do not have
claims data confirming that prescriptions
were filled, we likely missed cases that
were undiagnosed or incompletely as-
sessed, and some of the cases listed
were prescribed SGLT2i by practitioners
whose prescribing is not reflected in our
electronic health records. The relatively
lower presenting glucose observed in
the setting of SGLT2i-associated DKA is
likely due to the proposed pathologic
mechanisms (4). It is unclear if there
are specific characteristics that make
some patients more predisposed.
DKA in the setting of SGLT2i therapy is
unusual in that it disproportionately af-
fects thosewith type 2 diabetes and often
presents with glucose,300 mg/dL, mak-
ing recognition challenging. We would
recommend a high index of suspicion for
DKA in patients taking SGLT2i with unex-
plained malaise or gastrointestinal symp-
toms and recommendmeasuring urine or
plasma ketones in that setting. While its
occurrence is unusual, we should counsel
patients on the signs, symptoms, andpos-
sible precipitants of DKA even in the set-
ting of type 2 diabetes when prescribing
SGLT2i.
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